Sign up
Pharma Capital

Futura Medical highlights "huge interest" for erectile dysfunction gel based on Ipsos research

James Barder, chief executive officer at Futura Medical (LON:FUM) discusses the Ipsos findings that show its treatment for erectile dysfunction has the potential to be a US$1bn drug.

 

View full FUM profile

Futura Medical plc. Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.